immune checkpoint inhibitor

You have access
Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series
HIROSHI AOKI, NAOKI MATSUMOTO, HIROSHI TAKAHASHI, MASAYUKI HONDA, TOMOHIRO KANEKO, SHUHEI ARIMA, TOMOTAKA ISHII, TAKU MIZUTANI, RYOTA MASUZAKI, KAZUSHIGE NIREI, HIROAKI YAMAGAMI, MASAHIRO OGAWA, TATSUO KANDA, MITSUHIKO MORIYAMA and KATSUHIRO MIURA

Anticancer Research December 2021, 41 (12) 6225-6230; DOI: https://doi.org/10.21873/anticanres.15442
You have access
Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
YUJI NOJIMA, KATSUHIKO SHIMIZU, SHINSUKE SAISHO, AI MAEDA, TAKESHI KUROSAKI, KOJI KUROSE, TORU OGA, MIKIO OKA and MASAO NAKATA

Anticancer Research November 2021, 41 (11) 5469-5475; DOI: https://doi.org/10.21873/anticanres.15359
You have access
Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma
TAIGO KATO, AKIRA NAGAHARA, NORIHIKO KAWAMURA, WATARU NAKATA, TETSUJI SODA, KYOSUKE MATSUZAKI, KOJI HATANO, ATSUNARI KAWASHIMA, TAKESHI UJIKE, RYOICHI IMAMURA, KENSAKU NISHIMURA, SHINGO TAKADA, MASAO TSUJIHATA, SEIJI YAMAGUCHI, TETSUYA TAKAO, YASUTOMO NAKAI, MASASHI NAKAYAMA, NORIO NONOMURA and MOTOHIDE UEMURA

Anticancer Research November 2021, 41 (11) 5811-5816; DOI: https://doi.org/10.21873/anticanres.15398
You have access
Stereotactic and Hypofractionated Radiotherapy Associated With Immune Checkpoint Inhibitor Drugs: Analysis of Local Control, Toxicity, and Outcome in a Single Research Centre Case Study
DIMITRI ANZELLINI, VITALIANA DE SANCTIS, MAURIZIO VALERIANI, CHIARA REVERBERI, LUCA MARINELLI, MARIA MASSARO, GIANLUCA VULLO, GIUSEPPE FACONDO, RICCARDO CARLO SIGILLO, EMANUELE TOSI and MATTIA FALCHETTO OSTI

Anticancer Research October 2021, 41 (10) 5107-5116; DOI: https://doi.org/10.21873/anticanres.15327
You have access
Molecular Characteristics of Lymphocyte-predominant Triple-negative Breast Cancer
RITSUKO SASAKI, YOSHIYA HORIMOTO, YUKA YANAI, AIKO KURISAKI-ARAKAWA, ATSUSHI ARAKAWA, KATSUYA NAKAI, MITSUE SAITO and TSUYOSHI SAITO

Anticancer Research April 2021, 41 (4) 2133-2140; DOI: https://doi.org/10.21873/anticanres.14985
You have access
Complete Response of Bone Metastasis in Non-small Cell Lung Cancer With Pembrolizumab: Two Case Reports
YOHEI ASANO, NORIO YAMAMOTO, KATSUHIRO HAYASHI, AKIHIKO TAKEUCHI, SHINJI MIWA, KENTARO IGARASHI, HIROTAKA YONEZAWA, YOSHIHIRO ARAKI, SEI MORINAGA, KAZUO KASAHARA, TAKASHI SONE and HIROYUKI TSUCHIYA

Anticancer Research March 2021, 41 (3) 1693-1699; DOI: https://doi.org/10.21873/anticanres.14933
You have access
Serum Soluble Interleukin-2 Receptor as a Potential Biomarker for Immune-related Adverse Events
RYO TAKAI, YOHEI FUNAKOSHI, HIROTAKA SUTO, YOSHIAKI NAGATANI, YOSHINORI IMAMURA, MASANORI TOYODA, KIMIKAZU YAKUSHIJIN, NAOMI KIYOTA, KEN-ICHI HARADA, KIMIHIRO YAMASHITA, YOSHIHIRO KAKEJI and HIRONOBU MINAMI

Anticancer Research February 2021, 41 (2) 1021-1026; DOI: https://doi.org/10.21873/anticanres.14857
You have access
Significance of Pre-treatment Interferon-gamma Release in Patients With Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitors
TOMONORI HIRASHIMA, TOMOHIRO KANAI, HIDEKAZU SUZUKI, HIROKO YOSHIDA, AKANE MATSUSITA, HIROMI KAWASUMI, SHINGO NASU, AYAKO TANAKA, NAOKO MORISHITA, KUNIMITSU KAWAHARA, YOSHITAKA TAMURA and NORIO OKAMOTO

Anticancer Research December 2020, 40 (12) 6971-6978; DOI: https://doi.org/10.21873/anticanres.14721
You have access
Efficacy and Safety of Axitinib Therapy After Nivolumab for Patients With Metastatic Renal Cell Cancer
SHOTARO YASUOKA, TAKESHI YUASA, RYO FUJIWARA, YOSHINOBU KOMAI, NOBORU NUMAO, SHINYA YAMAMOTO, YUKIHIRO KONDO and JUNJI YONESE

Anticancer Research November 2020, 40 (11) 6493-6497; DOI: https://doi.org/10.21873/anticanres.14671
You have access
Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma
CHIHIRO FUSHIMI, ISAKU OKAMOTO, TAKASHI MATSUKI, TATSUO MASUBUCHI, TAKURO OKADA, HIROKI SATO, KIYOAKI TSUKAHARA, TAKAHITO KONDO, TAKU YAMASHITA, KENJI HANYU, GO OMURA, HIDEAKI TAKAHASHI, YUICHIRO TADA and KOUKI MIURA

Anticancer Research September 2020, 40 (9) 5277-5283; DOI: https://doi.org/10.21873/anticanres.14532

Main menu

User menu

Search

immune checkpoint inhibitor

Pages